Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells
Open Access
- 1 October 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 112 (7) , 2847-2857
- https://doi.org/10.1182/blood-2008-01-132951
Abstract
Previously, we showed that human umbilical cord blood (UCB) regulatory T cells (Tregs) could be expanded approximately 100-fold using anti-CD3/28 monoclonal antibody (mAb)–coated beads to provide T-cell receptor and costimulatory signals. Because Treg numbers from a single UCB unit are limited, we explored the use of cell-based artificial antigen-presenting cells (aAPCs) preloaded with anti-CD3/28 mAbs to achieve higher levels of Treg expansion. Compared with beads, aAPCs had similar expansion properties while significantly increasing transforming growth factor β (TGF-β) secretion and the potency of Treg suppressor function. aAPCs modified to coexpress OX40L or 4-1BBL expanded UCB Tregs to a significantly greater extent than bead- or nonmodified aAPC cultures, reaching mean expansion levels exceeding 1250-fold. Despite the high expansion and in contrast to studies using other Treg sources, neither OX40 nor 4-1BB signaling of UCB Tregs reduced in vitro suppression. UCB Tregs expanded with 4-1BBL expressing aAPCs had decreased levels of proapoptotic bim. UCB Tregs expanded with nonmodified or modified aAPCs versus beads resulted in higher survival associated with increased Treg persistence in a xeno-geneic graft-versus-host disease lethality model. These data offer a novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL.Keywords
This publication has 57 references indexed in Scilit:
- Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytesNature Medicine, 2007
- OX40 costimulation turns off Foxp3+ TregsBlood, 2007
- Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory MoleculesMolecular Therapy, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV diseaseAnnals of Surgical Oncology, 2006
- Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host diseaseBlood, 2006
- OX40 ligand shuts down IL-10-producing regulatory T cellsProceedings of the National Academy of Sciences, 2006
- The NF-κB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cellsProceedings of the National Academy of Sciences, 2006
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005
- Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITRBlood, 2005